|Document ID (ISN)||102846|
|Convention or series no.
||IARC Monographs 66
World Health Organization (WHO)
||IARC monographs on the evaluation of carcinogenic risks to humans - Some pharmaceutical drugs
||World Health Organization, Distribution and Sales Service, 1211 Genève 27, Switzerland, International Agency for Research on Cancer (IARC), 150 cours Albert Thomas, 69372 Lyon Cedex 08, France 1996. iv, 514p. Illus. Bibl.ref. Index. Price: CHF 80.00.
||This criteria document evaluates the following pharmaceutical compounds with respect to their carcinogenicity in humans: benzodiazepines and related compounds and phenytoin (diazepam, doxefazepam, estazolam, oxazepam, prazepam, ripazepam, temazepam, phenytoin); anti-oestrogenic compounds (droloxifene, tamoxifene, toremifene); hypolipidaemic drugs (clofibrate, gemfibrozil). Tamoxifene is classified in group 1 (carcinogenic in humans). Oxazepam and phenytoin are classified in group 2B (possibly carcinogenic in humans). All others fall under group 3 (not classifiable as to their carcinogenicity in humans).
||pharmaceutical products; WHO; carcinogenic effects; benzodiazepines; hazard evaluation; IARC
||mutagenic effects; literature survey; diazepam; oxazepam; criteria document; phenytoin; cholesterol; epidemiologic study; classification; oestrogens
||E - Books, reports, proceedings
|Country / State or Province||France|
||Toxic and dangerous substances
|Broad subject area(s)
Genetic factors in reaction to exposures